The depot GnRH agonist protocol improves the live birth rate per fresh embryo transfer cycle, but not the cumulative live birth rate in normal responders: a randomized controlled trial and molecular mechanism study

April 1, 2020Human ReproductionOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research investigates the impact of three controlled ovarian stimulation protocols on cumulative live birth rates after IVF/ICSI in normal responders.
Randomized controlled trial among 819 infertile women with normal ovarian response.
Participants assigned to GnRH antagonist, depot GnRHa, or long GnRHa protocols in a 1:1:1 ratio.
Evaluation of endometrial markers HOXA10, MEIS1, and LIF via quantitative real-time PCR and western blot.
Cumulative live birth rates were similar across protocols (GnRH antagonist: 71.4%, depot GnRHa: 75.5%, long GnRHa: 72.2%).
Live birth rate per fresh embryo transfer was significantly higher in the depot GnRHa group (62.6%) compared to long GnRHa (52.1%) and GnRH antagonist (45.6%), P < 0.05.
Endometrial expression of HOXA10, MEIS1, and LIF was significantly elevated in the depot GnRHa protocol, P < 0.05.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Randomized trial compares live birth rates in normal responders, indicating depot GnRH agonist may enhance outcomes.

No takes yet. Share an insight, caveat, or question.

Xu et al. (2020) studied this question.

View Full Paper

Ask AI

Bookmark

Share